Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 4 records, 1 pages
Search For: Biosimilar Insulin Lispro
Global Biosimilar Insulin Lispro Supply, Demand and Key Producers, 2024-2030
18 Feb 2024
Pharma & Healthcare
The global Biosimilar Insulin Lispro market size is expected to reach $ 633.5 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
Global Biosimilar Insulin Lispro Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
09 Jan 2024
Pharma & Healthcare
According to our (Global Info Research) latest study, the global Biosimilar Insulin Lispro market size was valued at USD 526.4 million in 2023 and is forecast to a readjusted size of USD 633.5 million by 2030 with a CAGR of 2.7% during review period.
USD3480.00
Add To Cart
Global Biosimilar Insulin Lispro Supply, Demand and Key Producers, 2023-2029
25 Feb 2023
Pharma & Healthcare
The global Biosimilar Insulin Lispro market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
Global Biosimilar Insulin Lispro Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
09 Jan 2023
Pharma & Healthcare
Insulin lispro Sanofi is a 'biosimilar medicine'. This means that it is highly similar to a biological medicine (also known as the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution
USD3480.00
Add To Cart
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: Biosimilar Insulin Lispro
Total: 4 records, 1 pages
The global Biosimilar Insulin Lispro market size is expected to reach $ 633.5 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
According to our (Global Info Research) latest study, the global Biosimilar Insulin Lispro market size was valued at USD 526.4 million in 2023 and is forecast to a readjusted size of USD 633.5 million by 2030 with a CAGR of 2.7% during review period.
USD3480.00
Add To Cart
The global Biosimilar Insulin Lispro market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
Insulin lispro Sanofi is a 'biosimilar medicine'. This means that it is highly similar to a biological medicine (also known as the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution
USD3480.00
Add To Cart
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>